title: Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?
authors.affiliation: Clinical Research, Centocor, 145 King of Prussia Road, R-4-1, Malvern, PA 19355, USA.
authors.forename: Emil
authors.initials: E
authors.lastname: Chuang
authors.forename: Alfred
authors.initials: A
authors.lastname: Del Vecchio
authors.forename: Steve
authors.initials: S
authors.lastname: Smolinski
authors.forename: Xiao-Yu
authors.initials: XY
authors.lastname: Song
authors.forename: Robert T
authors.initials: RT
authors.lastname: Sarisky
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects / Q000502:physiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000069285:Infliximab; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology / Q000821:virology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019562:Viral Load
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab